Wyeth to re-submit Viviant this year, expects advisory committee review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth plans to resubmit its osteoporosis drug Viviant (bazedoxifene) this year, and given the drug's safety concerns, the firm is expecting an FDA advisory committee review to follow. The selective estrogen receptor modulator has received two "approvable" letters since the initial NDA submission, with FDA requesting more information on the incidence of stroke and VTE. Even still, execs said in a March 17 presentation at the Cowen Health Care Conference that they are "pleased" with the drug's clinical profile. Wyeth also expects an approval decision for Viviant in Europe shortly, where it recently received a positive opinion
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.